Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Y. Han
Observed name:
Yafan Han
Institutions:
Tianjin Medical University Cancer Institute and Hospital,
Tianjin Medical University
Observed institutions:
Xinjiang Medical University,
Tianjin Medical University Cancer Institute and Hospital,
First Affiliated Hospital of Xinjiang Medical University,
Affiliated Hospital of Southwest Medical University,
University of Hong Kong - Shenzhen Hospital,
Tianjin Medical University
show all 6
ORCID:
0009-0004-9207-6930
Observed ORCID:
0009-0004-9207-6930
OpenAlex ID:
A5009043245
402P Updated results from the multicenter phase II, ALTER-C001 trial: Efficacy and safety of anlotinib plus XELOX regimen as first-line treatment followed by maintenance monotherapy of anlotinib for patients with mCRC
2022
·
Y. Jin
, Y. Han
, et al.
·
Annals of Oncology
·
1
518P Efficacy and safety of treatments in HR+HER2- advanced breast cancer after cyclin-dependent kinase 4/6 inhibitors progression: A network meta-analysis and scoping review
2025
·
Z. Tong
, L. Zhang
, et al.
·
Annals of Oncology
Ablation of myocardial autonomic ganglion plexus in the treatment of bradyarrhythmia A one-arm interventional study
2024
·
Mingliang Shao
, Chenhuan Yao
, et al.
·
Clinics
EP05.01-015 Validate Radiomics Features and XGBoost Model in Radiation Pneumonitis (RP) Prediction in Patients with Primary Lung Cancer: A MultiCenter Study
2022
·
J. Liu
, H. Sun
, et al.
·
Journal of Thoracic Oncology
PDF
Show more works
View as search
Works count:
4
Citation count:
1
H-index:
1
I10-index:
Year
Topic
Type